Cara Therapeutics Inc.

11.63-0.9300-7.40%Vol 932.13K1Y Perf -4.27%
Aug 11th, 2022 16:00 DELAYED
BID11.18 ASK12.20
Open12.54 Previous Close12.56
Pre-Market- After-Market11.55
 - -  -0.08 -0.69%
Target Price
24.71 
Analyst Rating
Strong Buy 1.29
Potential %
112.47 
Finscreener Ranking
★★★★+     56.67
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★     56.35
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★+     61.66
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
36.69 
Earnings Rating
Strong Buy
Market Cap624.82M 
Earnings Date
8th Aug 2022
Alpha-0.01 Standard Deviation0.15
Beta1.08 

Today's Price Range

11.5512.98

52W Range

7.4018.93

5 Year PE Ratio Range

-6.10164.70

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
3.19%
1 Month
23.07%
3 Months
52.83%
6 Months
11.83%
1 Year
-4.27%
3 Years
-49.50%
5 Years
-16.69%
10 Years
-

TickerPriceChg.Chg.%
CARA11.63-0.9300-7.40
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
92.00
-361.00
-360.00
-2 310.90
17.76
RevenueValueIndustryS&P 500US Markets
25.88M
0.48
18.01
121.54
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.28-0.0871.43
Q01 2022-0.56-0.527.14
Q04 2021-0.50-0.63-26.00
Q03 2021-0.36-0.0294.44
Q02 2021-0.55-0.61-10.91
Q01 2021-0.62-0.4724.19
Q04 2020-0.531.59400.00
Q03 2020-0.68-0.3548.53
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.2830.00Positive
9/2022 QR-0.365.26Positive
12/2022 FY-1.297.86Positive
12/2023 FY0.20-35.48Negative
Next Report Date-
Estimated EPS Next Report-0.28
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume932.13K
Shares Outstanding53.73K
Shares Float37.80M
Trades Count8.24K
Dollar Volume11.48M
Avg. Volume588.08K
Avg. Weekly Volume711.94K
Avg. Monthly Volume500.88K
Avg. Quarterly Volume551.40K

Cara Therapeutics Inc. (NASDAQ: CARA) stock closed at 11.63 per share at the end of the most recent trading day (a -7.4% change compared to the prior day closing price) with a volume of 932.13K shares and market capitalization of 624.82M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 80 people. Cara Therapeutics Inc. CEO is Derek T. Chalmers.

The one-year performance of Cara Therapeutics Inc. stock is -4.27%, while year-to-date (YTD) performance is -4.52%. CARA stock has a five-year performance of -16.69%. Its 52-week range is between 7.4 and 18.93, which gives CARA stock a 52-week price range ratio of 36.69%

Cara Therapeutics Inc. currently has a PE ratio of -5.20, a price-to-book (PB) ratio of 2.43, a price-to-sale (PS) ratio of 19.01, a price to cashflow ratio of 25.00, a PEG ratio of 2.32, a ROA of -40.37%, a ROC of -41.96% and a ROE of -44.05%. The company’s profit margin is 17.76%, its EBITDA margin is -360.00%, and its revenue ttm is $25.88 Million , which makes it $0.48 revenue per share.

Of the last four earnings reports from Cara Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.28 for the next earnings report. Cara Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Cara Therapeutics Inc. is Strong Buy (1.29), with a target price of $24.71, which is +112.47% compared to the current price. The earnings rating for Cara Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cara Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cara Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.95, ATR14 : 0.79, CCI20 : 155.43, Chaikin Money Flow : 0.03, MACD : 0.65, Money Flow Index : 60.49, ROC : 26.83, RSI : 59.05, STOCH (14,3) : 72.16, STOCH RSI : 0.62, UO : 61.32, Williams %R : -27.84), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cara Therapeutics Inc. in the last 12-months were: Christopher Posner (Sold 2 006 shares of value $25 416 ), Derek T. Chalmers (Sold 28 440 shares of value $429 248 ), Frederique Menzaghi (Sold 7 745 shares of value $97 628 ), Harrison M. Bains (Sold 7 200 shares of value $65 160 ), Jeffrey L. Ives (Sold 11 780 shares of value $163 787 ), Joana Goncalves (Sold 7 724 shares of value $101 960 ), Scott M. Terrillion (Sold 7 160 shares of value $85 162 ), Thomas Reilly (Sold 4 026 shares of value $51 405 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (85.71 %)
6 (85.71 %)
6 (85.71 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (14.29 %)
1 (14.29 %)
1 (14.29 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.29
Strong Buy
1.29
Strong Buy
1.29

Cara Therapeutics Inc.

Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

CEO: Derek T. Chalmers

Telephone: +1 203 406-3700

Address: 107 Elm Street, 9th Floor, Stamford 06902, CT, US

Number of employees: 80

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

63%38%

Bearish Bullish

58%42%

TipRanks News for CARA

Thu, 30 Jun 2022 18:15 GMT Analysts Offer Insights on Healthcare Companies: Cara Therapeutics (CARA) and Penumbra (PEN)

- TipRanks. All rights reserved.

Tue, 10 May 2022 10:45 GMT Analysts Offer Insights on Healthcare Companies: Cara Therapeutics (CARA) and Mereo Biopharma Group Plc (MREO)

- TipRanks. All rights reserved.

Tue, 12 Apr 2022 10:35 GMT Cara Therapeutics (CARA) Gets a Buy Rating from Needham

- TipRanks. All rights reserved.

News

Stocktwits